Alpha-lipoic acid, an anti-obesity agent?

abstract：:Introduction: Cyclin-dependent kinase 7 (CDK7) is a part of the CDK-activating kinase family (CAK) which has a key role in the cell cycle and transcriptional regulation. Several lines of evidence suggest that CDK7 is a promising therapeutic target for cancer. CDK7 selective inhibitors such as SY-5609 and CT7001 are in...

journal_title：Expert opinion on investigational drugs

authors： Liang H,Du J,Elhassan RM,Hou X,Fang H

更新日期：2021-01-01 00:00:00

abstract：INTRODUCTION:the search for effective inhibitors to multiple infectious agents including influenza, smallpox and hemorrhagic fever viruses is an area of active research as many of these agents pose dramatic health and economic challenges to the human population. Many of these infectious agents are not only endemic thre...

journal_title：Expert opinion on investigational drugs

authors： Narayanan A,Bailey C,Kashanchi F,Kehn-Hall K

更新日期：2011-02-01 00:00:00

abstract：:Gene transfer technology is under exploration to find therapies for the treatment of Parkinson's disease (PD) and other neurodegenerative disorders. The technology of genetic transfer can also be used as a neurobiological tool to understand the role of various genes in animal models of neurodegeneration. We describe t...

journal_title：Expert opinion on investigational drugs

authors： Frim DM,Kang UJ

更新日期：1999-10-01 00:00:00

abstract：BACKGROUND:Dexamethasone cipecilate is a corticosteroid nasal spray whose local efficacy durability has been improved by introduction of a liposoluble functional group to its chemical structure. This study was conducted to evaluate the efficacy of once-daily treatment with this drug in patients with perennial allergic ...

journal_title：Expert opinion on investigational drugs

authors： Gotoh M,Okubo K,Okuda M,Hamada C

更新日期：2010-12-01 00:00:00

abstract：:Proliferative diabetic retinopathy (PDR) demands both more effective and less expensive biologically based treatments. Our understanding of the pathophysiology of the disease is increasing as new biochemical pathways are identified. Most reports emphasize proangiogenic stimuli, with the natural inhibitory elements rec...

journal_title：Expert opinion on investigational drugs

authors： Hernández C,Simó R

更新日期：2007-08-01 00:00:00

abstract：:New therapies targeting critical elements of the cell cycle open novel and attractive avenues for the treatment of cancer patients. At present, the number of clinical trials that are registered with the European Organization for Research and Treatment of Cancer (EORTC) and with the US National Cancer Institute, which ...

journal_title：Expert opinion on investigational drugs

authors： Berg T,Bug G,Ottmann OG,Strebhardt K

更新日期：2012-08-01 00:00:00

abstract：INTRODUCTION:Oxidative stress toxicity (OST) has been implicated in almost all pathological conditions. Despite the widespread use of natural antioxidants, no pharmaceutical antioxidants have yet been developed or prescribed in medical practise. Antioxidant drugs such as Deferiprone and N-acetylcysteine can target esse...

journal_title：Expert opinion on investigational drugs

authors： Kontoghiorghes GJ,Kontoghiorghe CN

更新日期：2019-07-01 00:00:00

abstract：INTRODUCTION:The small tyrosine kinase inhibitor Imatinib Mesylate (Gleevec) protects against diabetes, but it is not known how. AREAS COVERED:It has been suggested that islet amyloid and fibrotic deposits promote beta-cell failure and death, leading to Type-2 diabetes. As Imatinib is known to possess anti-fibrotic/am...

journal_title：Expert opinion on investigational drugs

authors： Welsh N

更新日期：2012-11-01 00:00:00

abstract：:Argatroban, a synthetic peptidomimetic antithrombin agent, is the first clinical anticoagulant solely to target thrombin. For some time, this drug has been used in Japan for the management of thromboembolic disorders. Recently, it has been approved in Japan for use in thrombotic and ischaemic stroke. Despite a large n...

journal_title：Expert opinion on investigational drugs

authors： Jeske W,Walenga JM,Lewis BE,Fareed J

更新日期：1999-05-01 00:00:00

abstract：:Ovarian cancer leads to more fatalities than any other form of gynaecological cancer in North America and Europe. Over the last 30 years survival figures have improved somewhat due to improvements in diagnosis, surgery and chemotherapy. Despite these advances, the majority of patients will die from their disease, with...

journal_title：Expert opinion on investigational drugs

authors： Harries M,Kaye SB

更新日期：2001-09-01 00:00:00

abstract：:Since the introduction of the first through the skin (TTS) therapeutic in 1980, a total of 34 TTS products have been marketed and numerous drugs have been tested by more than 50 commercial organisations for their suitability for TTS delivery. Most of the agents which have been tested have had low molecular weights, du...

journal_title：Expert opinion on investigational drugs

authors： Cevc G

更新日期：1997-12-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Treatments of pulmonary arterial hypertension (PAH) that have so far proven efficacious are all based on the restoration of endothelium control of pulmonary vascular tone and structure, by administration of prostacyclins, endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Howeve...

journal_title：Expert opinion on investigational drugs

authors： Dewachter L,Dewachter C,Naeije R

更新日期：2010-04-01 00:00:00

abstract：:The outcome of patients with gastrointestinal stromal tumors has been dramatically improved by therapy with imatinib mesilate (imatinib mesylate), a KIT and platelet-derived growth factor (PDGFR) tyrosine kinase inhibitor. Unfortunately, the majority of patients eventually experience disease progression due to drug re...

journal_title：Expert opinion on investigational drugs

authors： Sankhala KK,Papadopoulos KP

更新日期：2007-10-01 00:00:00

abstract：:With the current standard chemotherapy regimens only approximately 25% of acute myelogenous leukaemia (AML) patients survive > 5 years. Aurora kinases are overexpressed in many human cancers. VX-680 inhibited Aurora-A, -B, -C and the FMS-like tyrosine kinase-3 with apparent inhibitory constants of 0.6, 18, 4.6 and 30 ...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2004-09-01 00:00:00

abstract：BACKGROUND:Pompholyx is a chronic relapsing inflammatory vesicobullous skin disease of the hands and feet belonging to the spectrum of eczema. Established treatments, both topical and systemic, are limited in efficacy, risk:benefit ratio and prevention of further relapses. New treatment options are needed. OBJECTIVE:T...

journal_title：Expert opinion on investigational drugs

authors： Wollina U

更新日期：2008-06-01 00:00:00

abstract：INTRODUCTION:The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) mainly comprise polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF, primary or post-PV/ET). Therapy in PV and ET focuses on minimizing thrombosis and bleeding risk, while in MF, prolongation of survival is an ...

journal_title：Expert opinion on investigational drugs

authors： Bose P,Verstovsek S

更新日期：2016-12-01 00:00:00

abstract：:Clinical trials showing the benefits of reducing the effects of TNF- alpha in rheumatoid arthritis have highlighted the key role of the cytokine TNF- alpha in this inflammatory condition. A new approach to reducing the effects of TNF- alpha is to decrease its synthesis by inhibiting TNF- alpha converting enzyme with G...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2002-07-01 00:00:00

abstract：:Introduction: The conventional management of most patients with metastatic urothelial carcinoma (UC) is platinum-based chemotherapy followed by immunotherapy. Erdafitinib is an option in post-platinum patients with activating mutations in fibroblast growth factor receptor (FGFR)-3 and -2. Salvage therapy with taxanes ...

journal_title：Expert opinion on investigational drugs

authors： McGregor BA,Sonpavde G

更新日期：2019-10-01 00:00:00

abstract：:Early breast carcinoma is defined as pathological stage 1 (pT1N0M0) tumour and its incidence has recently increased possibly due to the advent of mammography based mass screening. Overall survival of these patients is in general excellent, but more than 20% of them will eventually develop distant metastasis and die. T...

journal_title：Expert opinion on investigational drugs

authors： Sasano H

更新日期：2010-04-01 00:00:00

abstract：:Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the ...

journal_title：Expert opinion on investigational drugs

authors： Deacon CF

更新日期：2007-04-01 00:00:00

abstract：BACKGROUND:Armodafinil is a wake-promoting agent developed by Cephalon that was approved in mid-2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder. It is the R-enantiomer of the compound modafinil. Like modafinil, the mechanism of action for armoda...

journal_title：Expert opinion on investigational drugs

authors： Lankford DA

更新日期：2008-04-01 00:00:00

abstract：:Intravenous antihypertensive agents are used in clinical situations in which the immediate, precise control of blood pressure is a clinical necessity. Clevidipine is a new, vascular-selective, dihyrdopyridine Ca(2+) channel blocker, which exerts its hemodynamic effects through selective arterial vasodilation without e...

journal_title：Expert opinion on investigational drugs

authors： Gradman AH,Vivas Y

更新日期：2007-09-01 00:00:00

abstract：INTRODUCTION:Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the dystrophin (DMD) gene. Most patients die from respiratory failure or cardiomyopathy. There are significant unmet needs for treatments for DMD as the standard of care is principally limited to symptom relief throu...

journal_title：Expert opinion on investigational drugs

authors： Sheikh O,Yokota T

更新日期：2021-01-06 00:00:00

abstract：:IBC's 5(th) Annual Conference on Blood Substitutes was held on November 20-21, 1997. Approximately 100 medical researchers, academic scientists, blood substitute company speakers and representatives from major pharmaceutical companies with an interest or partner in the field attended. The papers presented focused on t...

journal_title：Expert opinion on investigational drugs

authors： Shorr RG

更新日期：1998-02-01 00:00:00

abstract：INTRODUCTION:The introduction of therapy with tumor necrosis factor antagonists (aTNF) was a cornerstone of treatment modalities in patients with ankylosing spondylitis (AS). After > 10 years of using aTNF, the introduction of aTNF therapy was a major step forward in the medical management of patients with spondyloarth...

journal_title：Expert opinion on investigational drugs

authors： Braun J,Baraliakos X,Heldmann F,Kiltz U

更新日期：2014-05-01 00:00:00

abstract：INTRODUCTION:Medical treatment of brain metastases (BM) is still a controversial issue in cancer therapy being mainly limited by the existence of the BBB. Temozolomide (TMZ) can cross BBB and several clinical trials have been performed attempting to demonstrate the activity of TMZ in combination with whole brain radiot...

journal_title：Expert opinion on investigational drugs

authors： Addeo R,Caraglia M

更新日期：2011-07-01 00:00:00

abstract：:Introduction: Therapeutic oligonucleotides have emerged as a promising new class of drug that could silence undruggable targets; they can potentially treat metabolic liver diseases such as nonalcoholic fatty liver disease (NAFLD), hereditary hemochromatosis and alpha 1 antitrypsin deficiency. Areas covered: This artic...

journal_title：Expert opinion on investigational drugs

authors： Alkhouri N,Gawrieh S

更新日期：2021-01-29 00:00:00

abstract：BACKGROUND:Interferon-alpha (IFN-α) is the traditional therapeutic agent for chronic myeloid leukemia (CML). The molecular mechanism of IFN-α efficacy in the treatment of CML is not fully clear. OBJECTIVES:To identify the peptides and/or proteins that bind to the proteins specifically expressed on the surface of IFN-α...

journal_title：Expert opinion on investigational drugs

authors： Liu J,Chen HC,Rao ZZ,Khan MA,Wan XX,Xu AH,Zhang N,Zhang DZ

更新日期：2011-12-01 00:00:00

abstract：:Thienopyridines have a well-established role in the treatment of coronary artery disease, especially in the setting of acute coronary syndromes and percutaneous coronary interventions. Ticlopidine, the first FDA-approved thienopyridine, was shown to be effective in reducing coronary events in high risk patients, but t...

journal_title：Expert opinion on investigational drugs

authors： Porto I,Giubilato S,De Maria GL,Biasucci LM,Crea F

更新日期：2009-09-01 00:00:00

abstract：:Endothelin-1 (ET-1) is enhanced and has been demonstrated to be a prognostic marker in patients with advanced stages of heart failure, acute ischaemic syndromes, myocardial infarction and pulmonary hypertension. Activation of the endothelin (ET) system is associated with adverse haemodynamic consequences in patients w...

journal_title：Expert opinion on investigational drugs

authors： Neunteufl T,Berger R,Pacher R

更新日期：2002-03-01 00:00:00